Clinical Trial Update: A Study of PTX-9908 Injection for Non-resectable HCC with TACE [Phase 1, Phase 2]

View source ↗

Summary

PTX-9908 Injection is in a Phase 1/2 study for non-resectable hepatocellular carcinoma in combination with transarterial chemoembolization (TACE), and recruitme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PTX-9908

Snippet

Sponsor: TCM Biotech International Corp. | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: RECRUITING